The life sciences sector in the North of England will receive £1.6 billion of investment over the next five years.
Figures gathered by the Northern Health Science Alliance looks at investments which will be made across the region over the time period.
Key investments include:
- Fujifilm Diosynth in Tees Valley has invested £5.7 million this year, building on a £6.7 million investment made in 2017 in high throughput process development of monoclonal antibodies, which will support its growing portfolio of projects to develop and manufacture life-changing medicines for its clients.
- Liverpool and Northumbria are now home to two of Proton Partners’ International Rutherford Cancer Centres with an initial investment of £70 million, with Rutherford Diagnostics recently announcing a £15 million diagnostic centre in the Liverpool Knowledge Quarter.
- QIAGEN are working with Health Innovation Manchester to develop a genomics campus in the heart of Manchester’s health innovation district. The new Genomic Health Innovation Campus aims to attract a cluster of companies to Manchester to drive pioneering research and development. The investment will create 250 new jobs while supporting more than 1,000 jobs indirectly in the Manchester corridor.
- The Leeds Medtech Hub has secured £70 million towards its £250 million investment target and its Nexus Centre is nearing completion. Alongside this, £15 million has been secured to deliver connected electronic patient records and a further £9.5 million to back Grow Medtech and its 20 new partners who will support work to deliver early stage medical technology innovation.
- At Sheffield Olympic Legacy Park, progress has been made on plans for an Orthopaedic and Rehabilitation Research and Innovation Centre and a Centre of Child Health and Technology.
Professor David Burn, chair of the Northern Health Science Alliance said: “We are delighted to see the strong support for health science research in the Industrial Strategy Life Sciences Sector Deal.
“We look forward to continuing to work with the Department of International Trade and the Office for Life Sciences to grow expertise, jobs and investment in the North of England’s vibrant life sciences sector.”
Latest figures for 2017 show the value of the life sciences sector in the North to be over £13.6 billion.
Geoff Davison CEO of BioNow said: “These investments demonstrate the commitment of industry to invest in the North of England and the importance of this part of the country to the wider UK.
“The industry welcomes a focus on the life sciences sector and encourages a continued focus on rebalancing Government investment into the North.”